Muhammad-Safuan Zainuddin, Saatheeyavaane Bhuvanendran, Ammu K. Radhakrishnan, A. Azman
{"title":"链霉菌次生代谢物化合物靶向的阿尔茨海默病相关蛋白:范围综述","authors":"Muhammad-Safuan Zainuddin, Saatheeyavaane Bhuvanendran, Ammu K. Radhakrishnan, A. Azman","doi":"10.3233/ADR-230065","DOIUrl":null,"url":null,"abstract":"Background: Alzheimer’s disease (AD) is a neurodegenerative disease that is characterized as rapid and progressive cognitive decline affecting 26 million people worldwide. Although immunotherapies are ideal, its clinical safety and effectiveness are controversial, hence, treatments are still reliant on symptomatic medications. Concurrently, the Streptomyces genus has attracted attention given its pharmaceutically beneficial secondary metabolites to treat neurodegenerative diseases. Objective: To present secondary metabolites from Streptomyces sp. with regulatory effects on proteins and identified prospective target proteins for AD treatment. Methods: Research articles published between 2010 and 2021 were collected from five databases and 83 relevant research articles were identified. Post-screening, only 12 research articles on AD-related proteins were selected for further review. Bioinformatics analyses were performed through the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) network, PANTHER Go-Slim classification system (PANTHER17.0), and Kyoto Encyclopedia of Genes and Genomes (KEGG) Mapper. Results: A total of 20 target proteins were identified from the 12 shortlisted articles. Amyloid-β, BACE1, Nrf-2, Beclin-1, and ATG5 were identified as the potential target proteins, given their role in initiating AD, mitigating neuroinflammation, and autophagy. Besides, 10 compounds from Streptomyces sp., including rapamycin, alborixin, enterocin, bonnevillamides D and E, caniferolide A, anhydroexfoliamycin, rhizolutin, streptocyclinone A and B, were identified to exhibit considerable regulatory effects on these target proteins. Conclusions: The review highlights several prospective target proteins that can be regulated through treatments with Streptomyces sp. compounds to prevent AD’s early stages and progression. Further identification of Streptomyces sp. compounds with potential anti-AD properties is recommended.","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"21 3","pages":"1335 - 1350"},"PeriodicalIF":2.8000,"publicationDate":"2023-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Alzheimer’s Disease-Related Proteins Targeted by Secondary Metabolite Compounds from Streptomyces: A Scoping Review\",\"authors\":\"Muhammad-Safuan Zainuddin, Saatheeyavaane Bhuvanendran, Ammu K. Radhakrishnan, A. Azman\",\"doi\":\"10.3233/ADR-230065\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Alzheimer’s disease (AD) is a neurodegenerative disease that is characterized as rapid and progressive cognitive decline affecting 26 million people worldwide. Although immunotherapies are ideal, its clinical safety and effectiveness are controversial, hence, treatments are still reliant on symptomatic medications. Concurrently, the Streptomyces genus has attracted attention given its pharmaceutically beneficial secondary metabolites to treat neurodegenerative diseases. Objective: To present secondary metabolites from Streptomyces sp. with regulatory effects on proteins and identified prospective target proteins for AD treatment. Methods: Research articles published between 2010 and 2021 were collected from five databases and 83 relevant research articles were identified. Post-screening, only 12 research articles on AD-related proteins were selected for further review. Bioinformatics analyses were performed through the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) network, PANTHER Go-Slim classification system (PANTHER17.0), and Kyoto Encyclopedia of Genes and Genomes (KEGG) Mapper. Results: A total of 20 target proteins were identified from the 12 shortlisted articles. Amyloid-β, BACE1, Nrf-2, Beclin-1, and ATG5 were identified as the potential target proteins, given their role in initiating AD, mitigating neuroinflammation, and autophagy. Besides, 10 compounds from Streptomyces sp., including rapamycin, alborixin, enterocin, bonnevillamides D and E, caniferolide A, anhydroexfoliamycin, rhizolutin, streptocyclinone A and B, were identified to exhibit considerable regulatory effects on these target proteins. Conclusions: The review highlights several prospective target proteins that can be regulated through treatments with Streptomyces sp. compounds to prevent AD’s early stages and progression. Further identification of Streptomyces sp. compounds with potential anti-AD properties is recommended.\",\"PeriodicalId\":73594,\"journal\":{\"name\":\"Journal of Alzheimer's disease reports\",\"volume\":\"21 3\",\"pages\":\"1335 - 1350\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2023-12-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Alzheimer's disease reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3233/ADR-230065\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's disease reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/ADR-230065","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
背景:阿尔茨海默病(AD)是一种神经退行性疾病,其特征是认知能力快速、进行性下降,影响着全球 2600 万人。虽然免疫疗法是理想的治疗方法,但其临床安全性和有效性仍存在争议,因此治疗仍依赖对症药物。与此同时,链霉菌属因其有益于治疗神经退行性疾病的医药次生代谢产物而备受关注。目的:介绍链霉菌中对蛋白质有调节作用的次级代谢产物,并确定治疗 AD 的前瞻性靶蛋白。方法:从五个数据库中收集 2010 年至 2021 年间发表的研究文章,并确定了 83 篇相关研究文章。经过筛选,仅选取了 12 篇有关 AD 相关蛋白的研究文章进行进一步审查。通过检索相互作用基因/蛋白搜索工具(STRING)网络、PANTHER Go-Slim分类系统(PANTHER17.0)和京都基因和基因组百科全书(KEGG)映射器进行生物信息学分析。结果:从 12 篇入围文章中共鉴定出 20 个目标蛋白。鉴于淀粉样蛋白-β、BACE1、Nrf-2、Beclin-1和ATG5在诱发AD、减轻神经炎症和自噬中的作用,它们被确定为潜在的靶蛋白。此外,10 种来自链霉菌的化合物,包括雷帕霉素、alborixin、enterocin、bonnevillamides D 和 E、caniferolide A、anhydroexfoliamycin、rhizolutin、streptocyclinone A 和 B 被鉴定出对这些靶蛋白具有相当大的调节作用。结论:本综述重点介绍了几种可通过链霉菌化合物进行调控的潜在靶蛋白,以预防注意力缺失症的早期阶段和进展。建议进一步鉴定具有潜在抗 AD 特性的链霉菌化合物。
Alzheimer’s Disease-Related Proteins Targeted by Secondary Metabolite Compounds from Streptomyces: A Scoping Review
Background: Alzheimer’s disease (AD) is a neurodegenerative disease that is characterized as rapid and progressive cognitive decline affecting 26 million people worldwide. Although immunotherapies are ideal, its clinical safety and effectiveness are controversial, hence, treatments are still reliant on symptomatic medications. Concurrently, the Streptomyces genus has attracted attention given its pharmaceutically beneficial secondary metabolites to treat neurodegenerative diseases. Objective: To present secondary metabolites from Streptomyces sp. with regulatory effects on proteins and identified prospective target proteins for AD treatment. Methods: Research articles published between 2010 and 2021 were collected from five databases and 83 relevant research articles were identified. Post-screening, only 12 research articles on AD-related proteins were selected for further review. Bioinformatics analyses were performed through the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) network, PANTHER Go-Slim classification system (PANTHER17.0), and Kyoto Encyclopedia of Genes and Genomes (KEGG) Mapper. Results: A total of 20 target proteins were identified from the 12 shortlisted articles. Amyloid-β, BACE1, Nrf-2, Beclin-1, and ATG5 were identified as the potential target proteins, given their role in initiating AD, mitigating neuroinflammation, and autophagy. Besides, 10 compounds from Streptomyces sp., including rapamycin, alborixin, enterocin, bonnevillamides D and E, caniferolide A, anhydroexfoliamycin, rhizolutin, streptocyclinone A and B, were identified to exhibit considerable regulatory effects on these target proteins. Conclusions: The review highlights several prospective target proteins that can be regulated through treatments with Streptomyces sp. compounds to prevent AD’s early stages and progression. Further identification of Streptomyces sp. compounds with potential anti-AD properties is recommended.